{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:32:13Z","timestamp":1793925133700,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02956-2","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T09:42:40Z","timestamp":1756633360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of U2AF1 mutation on erythroid differentiation and sensitivity to demethylation drug treatment"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuankai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"11","key":"2956_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrm.2017.86","volume":"18","author":"Y Shi","year":"2017","unstructured":"Shi Y. Mechanistic insights into precursor messenger RNA splicing by the spliceosome. Nat Rev Mol Cell Biol. 2017;18(11):655\u201370.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2956_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.gde.2017.10.008","volume":"48","author":"CL Kielkopf","year":"2018","unstructured":"Kielkopf CL. Insights from structures of cancer-relevant pre-mRNA splicing factors. Curr Opin Genet Dev. 2018;48:57\u201366.","journal-title":"Curr Opin Genet Dev"},{"key":"2956_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/45602","volume":"402","author":"L Merendino","year":"1999","unstructured":"Merendino L, Guth S, Bilbao D, Martinez C, Valcarcel J. Inhibition of msl-2 splicing by Sex-lethal reveals interaction between U2AF35 and the 3\u2032splice site AG. Nature. 1999;402:838\u201341.","journal-title":"Nature"},{"issue":"18","key":"2956_CR4","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.3390\/cancers14184406","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, et al. The biological and clinical consequences of RNA splicing factor U2AF1 mutation in myeloid malignancies. Cancers. 2022;14(18):4406.","journal-title":"Cancers"},{"key":"2956_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.molcel.2022.02.025","volume":"82","author":"G Biancon","year":"2022","unstructured":"Biancon G, Joshi P, Zimmer JT, Hunck T, Gao Y, Lessard MD, Courchaine E, Barentine A, Machyna M, Botti V, et al. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies. Mol Cell. 2022;82:1107\u201322.","journal-title":"Mol Cell"},{"key":"2956_CR6","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1172\/JCI91363","volume":"127","author":"BH Yip","year":"2017","unstructured":"Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, et al. The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. J Clin Investig. 2017;127:2206\u201321.","journal-title":"J Clin Investig"},{"issue":"5","key":"2956_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","volume":"27","author":"CL Shirai","year":"2015","unstructured":"Shirai CL, Ley JN, White BS, et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell. 2015;27(5):631\u201343.","journal-title":"Cancer Cell"},{"issue":"15","key":"2956_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/15353702211010130","volume":"246","author":"Z Liu","year":"2021","unstructured":"Liu Z, Dong X, Cao Z, et al. Mutant U2AF1-induced differential alternative splicing causes an oxidative stress in bone marrow stromal cells. Exp Biol Med (Maywood). 2021;246(15):1750\u20139.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2956_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmolb.2018.00080","volume":"5","author":"El Marabti","year":"2018","unstructured":"Marabti El. The cancer spliceome: reprograming of alternative splicing in cancer. Front Mol Biosci. 2018;5:80\u201391.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"2956_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.blre.2005.01.004","volume":"19","author":"DV Catenacci","year":"2005","unstructured":"Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19(6):301\u201319.","journal-title":"Blood Rev"},{"key":"2956_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fonc.2016.00151","volume":"6","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, et al. Unraveling the pathogenesis of MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype. Front Oncol. 2016;6:151\u201360.","journal-title":"Front Oncol"},{"issue":"21","key":"2956_CR12","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO.2012.48.0764","volume":"31","author":"MT Voso","year":"2013","unstructured":"Voso MT, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31(21):2671\u20137.","journal-title":"J Clin Oncol"},{"issue":"7123","key":"2956_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature05378","volume":"445","author":"JA Ribeil","year":"2007","unstructured":"Ribeil JA, et al. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature. 2007;445(7123):102\u20135.","journal-title":"Nature"},{"key":"2956_CR14","doi-asserted-by":"publisher","first-page":"28789","DOI":"10.1038\/srep28789","volume":"6","author":"H Shi","year":"2016","unstructured":"Shi H, et al. ASXL1 plays an important role in erythropoiesis. Sci Rep. 2016;6:28789\u2013800.","journal-title":"Sci Rep"},{"key":"2956_CR15","doi-asserted-by":"publisher","first-page":"19589","DOI":"10.1038\/srep19589","volume":"6","author":"B Zhao","year":"2016","unstructured":"Zhao B, et al. H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell function. Sci Rep. 2016;6:19589\u2013601.","journal-title":"Sci Rep"},{"issue":"6","key":"2956_CR16","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1172\/JCI91363","volume":"127","author":"BH Yip","year":"2017","unstructured":"Yip BH, et al. The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. J Clin Invest. 2017;127(6):2206\u201321.","journal-title":"J Clin Invest"},{"key":"2956_CR17","volume-title":"Refractory anemia with ring sideroblasts","author":"KL Sticco","year":"2020","unstructured":"Sticco KL, Al Obaidi NM. Refractory anemia with ring sideroblasts. Treasure Island (FL): StatPearls; 2020."},{"issue":"7367","key":"2956_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139.","journal-title":"Nature"},{"issue":"5","key":"2956_CR19","doi-asserted-by":"publisher","first-page":"e0175523","DOI":"10.1371\/journal.pone.0175523","volume":"12","author":"S Jin","year":"2017","unstructured":"Jin S, et al. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PLoS ONE. 2017;12(5):e0175523-0175536.","journal-title":"PLoS ONE"},{"issue":"1","key":"2956_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-018-0558-8","volume":"11","author":"Y Huang","year":"2018","unstructured":"Huang Y, et al. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS. J Hematol Oncol. 2018;11(1):19\u201331.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2956_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2011","unstructured":"Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53\u20137.","journal-title":"Nat Genet"},{"issue":"11","key":"2956_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/stem.2885","volume":"36","author":"A Bapat","year":"2018","unstructured":"Bapat A, et al. Myeloid disease mutations of splicing factor SRSF2 cause G2-M arrest and skewed differentiation of human hematopoietic stem and progenitor cells. Stem Cells. 2018;36(11):1663\u201375.","journal-title":"Stem Cells"},{"issue":"3","key":"2956_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101195","volume":"33","author":"AM Hunter","year":"2020","unstructured":"Hunter AM, Padron E. Molecular genetics of MDS\/MPN overlap syndromes. Best Pract Res Clin Haematol. 2020;33(3): 101195.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2956_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fphar.2020.01044","volume":"11","author":"P Teodorescu","year":"2020","unstructured":"Teodorescu P, et al. Targeting the microenvironment in MDS: the final Frontier. Front Pharmacol. 2020;11:1044\u201354.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2956_CR25","first-page":"1882","volume":"55","author":"K Usuki","year":"2014","unstructured":"Usuki K. Treatment of MDS. Rinsho Ketsueki. 2014;55(10):1882\u201392.","journal-title":"Rinsho Ketsueki"},{"key":"2956_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2017.04.005","volume":"58","author":"QQ Zheng","year":"2017","unstructured":"Zheng QQ, et al. Iron overload promotes erythroid apoptosis through regulating HIF-1a\/ROS signaling pathway in patients with myelodysplastic syndrome. Leuk Res. 2017;58:55\u201362.","journal-title":"Leuk Res"},{"key":"2956_CR27","first-page":"1","volume":"6","author":"A Abou Zahr","year":"2015","unstructured":"Abou Zahr A, et al. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med. 2015;6:1\u201316.","journal-title":"J Blood Med"},{"issue":"19","key":"2956_CR28","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1182\/blood-2013-02-451757","volume":"121","author":"JP Issa","year":"2013","unstructured":"Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 2013;121(19):3811\u20137.","journal-title":"Blood"},{"issue":"9","key":"2956_CR29","first-page":"1131","volume":"60","author":"K Usuki","year":"2019","unstructured":"Usuki K. Treatment of higher risk myelodysplastic syndromes. Rinsho Ketsueki. 2019;60(9):1131\u20139.","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"2956_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"22","key":"2956_CR31","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327.","journal-title":"Blood"},{"issue":"10","key":"2956_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049\u201359.","journal-title":"Blood"},{"issue":"27","key":"2956_CR33","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","volume":"30","author":"R Bejar","year":"2012","unstructured":"Bejar R, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376\u201382.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2956_CR34","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496\u2013506.","journal-title":"N Engl J Med"},{"issue":"9","key":"2956_CR35","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","volume":"124","author":"L Malcovati","year":"2014","unstructured":"Malcovati L, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513\u201321.","journal-title":"Blood"},{"issue":"4","key":"2956_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/leu.2014.301","volume":"29","author":"D Inoue","year":"2015","unstructured":"Inoue D, et al. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia. 2015;29(4):847\u201357.","journal-title":"Leukemia"},{"issue":"4","key":"2956_CR37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/leu.2014.303","volume":"29","author":"T Okeyo-Owuor","year":"2015","unstructured":"Okeyo-Owuor T, White BS, Chatrikhi R, et al. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia. 2015;29(4):909\u201317.","journal-title":"Leukemia"},{"issue":"39","key":"2956_CR38","doi-asserted-by":"publisher","first-page":"21646","DOI":"10.1021\/jacs.3c08204","volume":"145","author":"X He","year":"2023","unstructured":"He X, Yuan J, Gao Zi, Wang Y. Promoter R-loops recruit U2AF1 to modulate its phase separation and RNA splicing. J Am Chem Soc. 2023;145(39):21646\u201360.","journal-title":"J Am Chem Soc"},{"issue":"11","key":"2956_CR39","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1128\/MCB.25.11.4727-4741.2005","volume":"25","author":"K Ghoshal","year":"2005","unstructured":"Ghoshal K, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25(11):4727\u201341.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2956_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8\u201313.","journal-title":"Int J Cancer"},{"issue":"11","key":"2956_CR41","first-page":"2760","volume":"30","author":"LH Li","year":"1970","unstructured":"Li LH, et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30(11):2760\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"2956_CR42","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","volume":"6","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe T, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2956_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/leu.2013.269","volume":"28","author":"F Traina","year":"2014","unstructured":"Traina F, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78\u201387.","journal-title":"Leukemia"},{"issue":"11","key":"2956_CR44","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.18632\/oncotarget.23882","volume":"9","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms. Oncotarget. 2018;9(11):9714\u201327.","journal-title":"Oncotarget"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02956-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:02:19Z","timestamp":1758096139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02956-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02956-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"459"}}